Nothing Special   »   [go: up one dir, main page]

HRP20160605T1 - Tetraciklički spoj - Google Patents

Tetraciklički spoj Download PDF

Info

Publication number
HRP20160605T1
HRP20160605T1 HRP20160605TT HRP20160605T HRP20160605T1 HR P20160605 T1 HRP20160605 T1 HR P20160605T1 HR P20160605T T HRP20160605T T HR P20160605TT HR P20160605 T HRP20160605 T HR P20160605T HR P20160605 T1 HRP20160605 T1 HR P20160605T1
Authority
HR
Croatia
Prior art keywords
solvate
salt
compound according
active ingredient
ingredient contains
Prior art date
Application number
HRP20160605TT
Other languages
English (en)
Inventor
Kazutomo Kinoshita
Kohsuke Asoh
Noriyuki Furuichi
Toshiya Ito
Hatsuo Kawada
Nobuya Ishii
Hiroshi Sakamoto
Woo Sang Hong
Min Jeong Park
Yoshiyuki Ono
Yasuharu Kato
Kenji Morikami
Takashi Emura
Nobuhiro Oikawa
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43308919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20160605(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of HRP20160605T1 publication Critical patent/HRP20160605T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)

Claims (5)

1. Spoj, naznačen time što je 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-okso-6,11-dihidro-5H-benzo[b]karbazol-3-karbonitril, ili njegova sol ili solvat.
2. Medikament, naznačen time što kao aktivni sastojak sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu sol ili solvat.
3. Inhibitor ALK, naznačen time što kao aktivni sastojak sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu sol ili solvat.
4. Farmaceutska tvar namijenjena profilaksi ili liječenju raka, metastaza raka, depresije ili poremećaja kognitivnih funkcija, naznačena time što kao aktivni sastojak sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu sol ili solvat.
5. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu sol ili solvat, kao i jedan ili više farmaceutski prihvatljivih nosača.
HRP20160605TT 2009-06-10 2016-06-06 Tetraciklički spoj HRP20160605T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009139691 2009-06-10
PCT/JP2010/059785 WO2010143664A1 (ja) 2009-06-10 2010-06-09 ４環性化合物
EP10786195.7A EP2441753B1 (en) 2009-06-10 2010-06-09 Tetracyclic compound

Publications (1)

Publication Number Publication Date
HRP20160605T1 true HRP20160605T1 (hr) 2016-07-01

Family

ID=43308919

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20160605TT HRP20160605T1 (hr) 2009-06-10 2016-06-06 Tetraciklički spoj
HRP20180615TT HRP20180615T1 (hr) 2009-06-10 2018-04-18 Tetraciklički spojevi
HRP20192022TT HRP20192022T1 (hr) 2009-06-10 2019-11-07 Tetraciklički spojevi

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20180615TT HRP20180615T1 (hr) 2009-06-10 2018-04-18 Tetraciklički spojevi
HRP20192022TT HRP20192022T1 (hr) 2009-06-10 2019-11-07 Tetraciklički spojevi

Country Status (40)

Country Link
US (6) US9126931B2 (hr)
EP (4) EP3613729A1 (hr)
JP (2) JP4588121B1 (hr)
KR (1) KR101351120B1 (hr)
CN (1) CN102459172B (hr)
AR (1) AR077025A1 (hr)
AU (1) AU2010259588B2 (hr)
BR (1) BRPI1011649B1 (hr)
CA (1) CA2764653C (hr)
CL (1) CL2011002433A1 (hr)
CO (1) CO6430460A2 (hr)
CR (1) CR20110492A (hr)
CY (2) CY1117752T1 (hr)
DK (3) DK2975024T3 (hr)
EC (1) ECSP12011573A (hr)
ES (3) ES2668775T3 (hr)
FR (1) FR17C1019I2 (hr)
HK (1) HK1165794A1 (hr)
HR (3) HRP20160605T1 (hr)
HU (4) HUE028278T2 (hr)
IL (1) IL216817A (hr)
LT (3) LT3345903T (hr)
LU (1) LUC00022I2 (hr)
MA (1) MA33418B1 (hr)
MX (1) MX2011013306A (hr)
MY (1) MY159850A (hr)
NL (1) NL300876I2 (hr)
NO (2) NO2975024T3 (hr)
NZ (1) NZ597477A (hr)
PE (1) PE20121065A1 (hr)
PL (3) PL2441753T3 (hr)
PT (3) PT2441753E (hr)
RS (1) RS58855B1 (hr)
RU (2) RU2585622C3 (hr)
SG (1) SG175707A1 (hr)
SI (3) SI2441753T1 (hr)
TW (2) TWI624457B (hr)
UA (1) UA107796C2 (hr)
WO (1) WO2010143664A1 (hr)
ZA (1) ZA201106938B (hr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY159850A (en) * 2009-06-10 2017-02-15 Chugai Pharmaceutical Co Ltd Tetracyclic compounds
KR101362589B1 (ko) * 2010-08-20 2014-02-12 추가이 세이야쿠 가부시키가이샤 4환성 화합물을 포함하는 조성물
JP5006987B2 (ja) * 2010-11-22 2012-08-22 中外製薬株式会社 ４環性化合物を含む医薬
KR102110794B1 (ko) * 2011-10-31 2020-05-15 더 메서디스트 하스피틀 리서치 인스티튜트 인간의 신경교종을 치료하기 위한 모노아마이드 옥시다아제(Monoamide oxidase,MAO) 타겟팅/시커(seeker) 부분(moiety)을 포함하는 조성물
ES2570976T3 (es) * 2012-03-06 2016-05-23 Cephalon Inc Derivado de 2,4-diaminopirimidina bicíclico condensado como inhibidor dual de ALK y FAK
SI2902029T1 (sl) 2012-09-25 2018-11-30 Chugai Seiyaku Kabushiki Kaisha Inhibitor ret
WO2014100431A1 (en) 2012-12-20 2014-06-26 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
WO2014121654A1 (zh) * 2013-02-05 2014-08-14 山东轩竹医药科技有限公司 四并环激酶抑制剂
ES2904277T3 (es) * 2013-04-02 2022-04-04 Oxular Acquisitions Ltd Productos intermedios útiles en la preparación de derivados de naftilurea útiles como inhibidores de quinasa
CN104109168B (zh) * 2013-04-20 2017-02-15 山东轩竹医药科技有限公司 四并环激酶抑制剂
CN104130241A (zh) * 2013-05-05 2014-11-05 山东轩竹医药科技有限公司 四并环激酶抑制剂
CN104177332A (zh) * 2013-05-20 2014-12-03 中国科学院上海药物研究所 酰胺基取代的吲哚并萘酮衍生物及其医药用途
CN104177342B (zh) * 2013-05-21 2018-01-05 中国科学院上海药物研究所 杂环基取代的吲哚并萘酮衍生物及其医药用途
WO2014190949A1 (zh) * 2013-06-01 2014-12-04 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
CN104230960B (zh) * 2013-06-06 2017-02-15 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
MX2015017629A (es) 2013-06-18 2016-04-15 Novartis Ag Combinaciones farmaceuticas.
CN104804016B (zh) * 2014-01-23 2017-06-20 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
CN106456651A (zh) 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
WO2015163447A1 (ja) * 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物の新規結晶
RU2720680C2 (ru) * 2014-06-18 2020-05-12 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция, содержащая неионные сурфактанты
TWI718102B (zh) * 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
CN107108586B (zh) 2014-09-29 2020-07-10 山东轩竹医药科技有限公司 多环类间变性淋巴瘤激酶抑制剂
CN105566307B (zh) * 2014-10-11 2019-04-23 中国科学院上海药物研究所 一类杂环取代的吲哚并萘酮衍生物、其制备方法、药物组合物及其用途
CN104402862B (zh) 2014-11-12 2016-10-05 苏州明锐医药科技有限公司 艾立替尼的制备方法
EP3246047A4 (en) 2015-01-16 2018-08-22 Chugai Seiyaku Kabushiki Kaisha Combination drug
US9573932B2 (en) * 2015-03-02 2017-02-21 Yong Xu Synthesis of intermediates in the preparation of ALK inhibitor
ES2875151T3 (es) * 2015-03-11 2021-11-08 Int Flavors & Fragrances Inc Procedimientos para la preparación de malonatos insaturados
US10259816B2 (en) 2015-04-24 2019-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
CN108290835B (zh) * 2015-09-23 2022-03-08 达纳-法伯癌症研究所股份有限公司 Alk和srpk的抑制剂和使用方法
CN105777710B (zh) * 2016-04-05 2018-09-04 湖南欧亚药业有限公司 一种艾乐替尼的合成方法
CN106946650B (zh) * 2017-03-01 2021-06-08 南京远淑医药科技有限公司 一种盐酸阿雷替尼中间体的合成方法
CN106928125A (zh) * 2017-04-21 2017-07-07 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼中间体的制备方法
CN107033125B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN107129488A (zh) * 2017-04-21 2017-09-05 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼的制备方法
CN106928185B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106892860B (zh) * 2017-04-21 2019-08-02 湖南博奥德药业有限公司 一种艾乐替尼中间体的制备方法
CN106928184B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN107033124B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106995433A (zh) * 2017-04-21 2017-08-01 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼的制备方法
EP3619207B1 (en) 2017-05-04 2021-06-23 Basf Se Substituted 5-(haloalkyl)-5-hydroxy-isoxazolines for combating phytopathogenic fungi
CN110891947B (zh) * 2017-07-05 2022-11-25 北京费森尤斯卡比医药有限公司 制备艾乐替尼或其药学上可接受的盐的方法
JP7054134B2 (ja) * 2017-12-07 2022-04-13 国立大学法人京都大学 ベンゾ［ｂ］カルバゾール化合物及びそれを用いたイメージング
CA3085645C (en) 2017-12-13 2024-01-16 Shanghaitech University Alk protein degraders and their use in cancer therapy
CN108178743A (zh) * 2018-02-08 2018-06-19 安庆奇创药业有限公司 一种艾乐替尼关键中间体的制备方法
JP7367908B2 (ja) * 2018-04-09 2023-10-24 上海科技大学 標的タンパク質分解化合物、その抗腫瘍応用、その中間体および中間体の応用
WO2019211868A1 (en) * 2018-04-30 2019-11-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl) piperidin-1-yl]-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile hydrochloride
US20210290630A1 (en) 2018-06-29 2021-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing poorly-soluble basic medicine
AU2019337018B2 (en) * 2018-09-04 2024-03-07 Chugai Seiyaku Kabushiki Kaisha Method of producing tetracyclic compound
AU2019348006A1 (en) * 2018-09-27 2021-02-18 Dana-Farber Cancer Institute, Inc. Degraders that target Alk and therapeutic uses thereof
CN109438218B (zh) * 2018-10-23 2021-04-09 成都艾必克医药科技有限公司 一种盐酸艾乐替尼中间体2-(4-乙基-3-碘苯基)-2-甲基丙酸的合成方法
CN109384664B (zh) * 2018-11-20 2021-04-13 成都正善达生物医药科技有限公司 一种艾乐替尼中间体的制备方法
EP3556754A1 (en) 2018-12-07 2019-10-23 Fresenius Kabi iPSUM S.r.l. Process for the preparation of alectinib
CN111349012B (zh) * 2018-12-21 2023-01-10 上海复星星泰医药科技有限公司 一种卤代芳烃类化合物的制备方法及其中间体
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN110590739A (zh) * 2019-09-20 2019-12-20 中国药科大学 一种艾乐替尼的制备方法
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3206965A1 (en) 2021-01-29 2022-08-04 Chugai Seiyaku Kabushiki Kaisha Drug composition for treating pediatric cancers
WO2022214681A1 (en) 2021-04-09 2022-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
CN115340523B (zh) * 2021-05-12 2023-12-15 盛世泰科生物医药技术(苏州)股份有限公司 一种具有alk抑制活性的化合物及其制备方法和用途
EP4424313A1 (en) 2021-10-28 2024-09-04 Chugai Seiyaku Kabushiki Kaisha Syrup preparation
WO2023161233A1 (en) * 2022-02-22 2023-08-31 Synthon B.V. Solid forms of alectinib and alectinib salts
CN115677659B (zh) * 2022-10-11 2024-03-22 枣庄市润安制药新材料有限公司 一种阿雷替尼的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0892090A (ja) * 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
DK0695755T3 (da) 1994-08-04 1999-06-28 Hoffmann La Roche Pyrrolocarbazoler
JPH08291285A (ja) * 1995-04-21 1996-11-05 Fuji Photo Film Co Ltd 感光性組成物及びそれを用いた要素
YU48398A (sh) * 1996-05-01 2000-12-28 Eli Lily And Company Inhibitori halo-supstituisane protein kinaze c
CA2372032A1 (en) * 1999-05-14 2000-11-23 Rodney W. Rickards Compounds and therapeutic methods
JP2007501857A (ja) * 2003-02-28 2007-02-01 イノテック ファーマシューティカルズ コーポレーション 四環系ベンズアミド誘導体およびその使用方法
ES2263862T3 (es) * 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7378414B2 (en) * 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
ATE400573T1 (de) * 2003-11-21 2008-07-15 Novartis Pharma Gmbh 1h-imidazochinolinderivate als proteinkinaseinhibitoren
EP1694647B1 (en) 2003-12-12 2016-11-09 Merck Canada Inc. Cathepsin cysteine protease inhibitors
TW200609215A (en) 2004-03-19 2006-03-16 Speedel Experimenta Ag Organic compounds
US7973061B2 (en) * 2004-03-31 2011-07-05 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
CN101023064B (zh) 2004-08-26 2011-02-16 辉瑞大药厂 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
US7091202B2 (en) * 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
CA2626446A1 (en) * 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as ppar modulators
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
AU2007309427B2 (en) * 2006-10-23 2013-02-28 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
JP2010524953A (ja) 2007-04-17 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
CN101754956B (zh) 2007-07-20 2014-04-23 内尔维阿诺医学科学有限公司 作为具有激酶抑制剂活性的取代的吲唑衍生物
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
WO2010128324A1 (en) 2009-05-07 2010-11-11 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
MY159850A (en) * 2009-06-10 2017-02-15 Chugai Pharmaceutical Co Ltd Tetracyclic compounds
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
KR101362589B1 (ko) * 2010-08-20 2014-02-12 추가이 세이야쿠 가부시키가이샤 4환성 화합물을 포함하는 조성물
SI2902029T1 (sl) * 2012-09-25 2018-11-30 Chugai Seiyaku Kabushiki Kaisha Inhibitor ret
CN106456651A (zh) * 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
WO2015163447A1 (ja) * 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物の新規結晶
RU2720680C2 (ru) * 2014-06-18 2020-05-12 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция, содержащая неионные сурфактанты
TWI718102B (zh) * 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體

Also Published As

Publication number Publication date
UA107796C2 (en) 2015-02-25
RU2011154150A (ru) 2013-07-20
TW201103537A (en) 2011-02-01
SI2975024T1 (en) 2018-05-31
CY2017026I1 (el) 2017-11-14
SI3345903T1 (sl) 2020-02-28
EP3345903A1 (en) 2018-07-11
HRP20180615T1 (hr) 2018-06-01
IL216817A (en) 2016-05-31
EP2441753B1 (en) 2016-03-30
DK2975024T3 (en) 2018-04-23
AU2010259588B2 (en) 2015-05-28
PT2441753E (pt) 2016-06-16
HK1165794A1 (en) 2012-10-12
US20150150845A1 (en) 2015-06-04
US20160340308A1 (en) 2016-11-24
ES2575084T3 (es) 2016-06-24
JP2011016830A (ja) 2011-01-27
MY159850A (en) 2017-02-15
EP3613729A1 (en) 2020-02-26
HRP20192022T1 (hr) 2020-02-07
US20230142119A1 (en) 2023-05-11
LT2975024T (lt) 2018-06-11
NO2017026I2 (no) 2017-06-12
TW201613858A (en) 2016-04-16
KR20120034677A (ko) 2012-04-12
SI2441753T1 (sl) 2016-07-29
CO6430460A2 (es) 2012-04-30
PL2975024T3 (pl) 2018-09-28
US20220306578A1 (en) 2022-09-29
RU2015156881A (ru) 2019-01-18
LTC2441753I2 (lt) 2019-02-25
LT3345903T (lt) 2019-12-10
EP2975024A1 (en) 2016-01-20
NZ597477A (en) 2014-03-28
LUC00022I1 (hr) 2017-06-15
FR17C1019I2 (fr) 2018-04-27
US20200017442A1 (en) 2020-01-16
ES2668775T3 (es) 2018-05-22
TWI531367B (zh) 2016-05-01
NO2017026I1 (no) 2017-06-12
EP2441753A1 (en) 2012-04-18
AR077025A1 (es) 2011-07-27
BRPI1011649A2 (pt) 2021-04-20
ES2759510T3 (es) 2020-05-11
RS20110548A1 (en) 2012-08-31
MA33418B1 (fr) 2012-07-03
EP2975024B1 (en) 2018-03-28
EP2441753A4 (en) 2014-08-27
ZA201106938B (en) 2012-12-27
US9440922B2 (en) 2016-09-13
NL300876I1 (nl) 2017-06-14
PL2441753T3 (pl) 2016-09-30
WO2010143664A1 (ja) 2010-12-16
DK3345903T3 (da) 2019-11-11
RU2015156881A3 (hr) 2019-08-08
CN102459172B (zh) 2015-06-24
HUE039167T2 (hu) 2018-12-28
CY2017026I2 (el) 2017-11-14
RU2585622C3 (ru) 2021-08-02
MX2011013306A (es) 2012-01-12
PL3345903T3 (pl) 2020-02-28
IL216817A0 (en) 2012-02-29
HUS1700026I1 (hu) 2017-07-28
RU2725140C2 (ru) 2020-06-30
CA2764653C (en) 2018-01-02
ECSP12011573A (es) 2012-02-29
PE20121065A1 (es) 2012-08-28
HUE028278T2 (en) 2016-12-28
CL2011002433A1 (es) 2012-02-17
CA2764653A1 (en) 2010-12-16
TWI624457B (zh) 2018-05-21
DK2441753T3 (en) 2016-05-30
SG175707A1 (en) 2011-12-29
HUE046402T2 (hu) 2020-03-30
CR20110492A (es) 2012-03-08
CY1117752T1 (el) 2017-05-17
CN102459172A (zh) 2012-05-16
PT2975024T (pt) 2018-05-14
EP3345903B1 (en) 2019-10-09
NL300876I2 (nl) 2017-07-11
RU2585622C2 (ru) 2016-05-27
RS58855B1 (sr) 2019-07-31
US9126931B2 (en) 2015-09-08
JP4588121B1 (ja) 2010-11-24
JP5628603B2 (ja) 2014-11-19
BRPI1011649B1 (pt) 2021-11-30
PT3345903T (pt) 2019-12-09
LTPA2017017I1 (lt) 2017-06-26
JPWO2010143664A1 (ja) 2012-11-29
FR17C1019I1 (hr) 2017-07-21
KR101351120B1 (ko) 2014-01-15
LUC00022I2 (hr) 2017-09-08
US20120083488A1 (en) 2012-04-05
AU2010259588A1 (en) 2011-10-06
NO2975024T3 (hr) 2018-08-25

Similar Documents

Publication Publication Date Title
HRP20160605T1 (hr) Tetraciklički spoj
HRP20171175T1 (hr) Novi triciklički spojevi
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
WO2010092090A3 (en) Novel salts of sitagliptin
WO2013147649A3 (ru) ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
MX359288B (es) Forma iv del clorhidrato de ivabradina.
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2013188283A8 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
EA201500112A1 (ru) 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств
EP2722042A4 (en) INDANONE DERIVATIVES, THEIR OPTICAL ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
TN2015000135A1 (en) Modified release formulations for oprozomib
EA201201109A1 (ru) Прасугрель в тонкоизмельченной кристаллической форме и фармацевтическая композиция, содержащая его
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
EP2769716A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING FLUOXETINE AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING HEMATO-ENCEPHALIC BARRIER DISORDERS
PL420169A1 (pl) N-Guanylowe pochodne 9-amino-5,11-dimetylo-5H-indolo[2,3-b]chinoliny, sposób ich otrzymywania i zawierające je środki farmaceutyczne
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
MX356245B (es) Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3'h-espiro[ciclohexan-1,1´-pirano[3,4,b] indol]-4-amina y un gabapentinoide.
WO2009108017A3 (en) New pyruvate derivatives with neuroprotective effect, process for preparing the same and pharmaceutical composition comprising the same
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate